Literature DB >> 1761118

Has the incidence of multiple myeloma in old age been underestimated? The myeloma project of health region I in Norway. I.

F Wisløff1, P Andersen, T R Andersson, E Brandt, C Eika, K Fjaestad, B Ly, K Løvåsen, B R Strøm, G E Tjønnfjord.   

Abstract

All patients in the region with newly discovered M components were registered from 15 Aug. 1984-31 Dec. 1986. Among a total of 393 patients enrolled, 162 had multiple myeloma (MM). The incidence rate was 6.6 per 100,000 population per year (age-adjusted to the European standard population), which is somewhat higher than previous reports based on hospital and autopsy records. In particular, the incidence rate was higher in the greater than 70 age group. Thus, the median age was 72 yr, which is the highest reported. As many as 71 (44%) of the 162 MM patients were asymptomatic; these asymptomatic patients had the same age distribution as the symptomatic ones. The stage distribution, occurrence of risk factors, response to chemotherapy, response duration and survival were similar in the age groups below and above the median and, in multivariate survival analysis, age was not an independent risk factor.

Entities:  

Mesh:

Year:  1991        PMID: 1761118     DOI: 10.1111/j.1600-0609.1991.tb01856.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  7 in total

Review 1.  Therapeutic options in the treatment of multiple myeloma: pharmacoeconomic and quality-of-life considerations.

Authors:  F Wisløff; N Gulbrandsen; E Nord
Journal:  Pharmacoeconomics       Date:  1999-10       Impact factor: 4.981

2.  Cost-utility analysis of melphalan plus prednisone with or without interferon-alpha 2b in newly diagnosed multiple myeloma. Results from a randomised controlled trial.

Authors:  E Nord; F Wisløff; M Hjorth; J Westin
Journal:  Pharmacoeconomics       Date:  1997-07       Impact factor: 4.981

3.  Patterns of multiple myeloma during the past 5 decades: stable incidence rates for all age groups in the population but rapidly changing age distribution in the clinic.

Authors:  Ingemar Turesson; Ramon Velez; Sigurdur Y Kristinsson; Ola Landgren
Journal:  Mayo Clin Proc       Date:  2010-03       Impact factor: 7.616

4.  Epidemiology of the M-component immunoglobulin types of multiple myeloma.

Authors:  L J Herrinton; P A Demers; T D Koepsell; N S Weiss; J R Daling; J W Taylor; J L Lyon; G M Swanson; R S Greenberg
Journal:  Cancer Causes Control       Date:  1993-03       Impact factor: 2.506

5.  Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group.

Authors:  Heinz Ludwig; Brian G M Durie; Vanessa Bolejack; Ingemar Turesson; Robert A Kyle; Joan Blade; Rafael Fonseca; Meletios Dimopoulos; Kazuyuki Shimizu; Jesus San Miguel; Jan Westin; Jean-Luc Harousseau; Meral Beksac; Mario Boccadoro; Antonio Palumbo; Bart Barlogie; Chaim Shustik; Michele Cavo; Philip R Greipp; Douglas Joshua; Michel Attal; Pieter Sonneveld; John Crowley
Journal:  Blood       Date:  2008-02-11       Impact factor: 22.113

Review 6.  Targeted treatments for multiple myeloma: specific role of carfilzomib.

Authors:  Dhivya Sugumar; Jesse Keller; Ravi Vij
Journal:  Pharmgenomics Pers Med       Date:  2015-01-20

7.  More frequent IgD and reduced CD200 expression in Chinese patients younger than 50 years old with multiple myeloma: a multicenter analysis.

Authors:  Jin Lu; Jing Lu; Wenming Chen; Jing Wang; Yuliang Huo; Jian Hou; Xiaojun Huang
Journal:  Drug Des Devel Ther       Date:  2016-11-08       Impact factor: 4.162

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.